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Malignant pleural mesothelioma (MPM) is a rare and highly aggressive neoplasm
that arises from the pleural, pericardial, or peritoneal lining. Although surgery,
chemotherapy, radiotherapy, and combinations of these therapies are used to
treat MPM, the median survival of such patients is dismal. Therefore, there is a
compelling need to develop novel therapeutics with different modes of action.
Ganglioside GM2 is a glycolipid that has been shown to be overexpressed in vari-
ous types of cancer. However, there are no published reports regarding the use
of GM2 as a potential therapeutic target in cases of MPM. In this study, we eval-
uated the efficacy of the anti-GM2 antibody BIW-8962 as an anti-MPM therapeu-
tic using in vitro and in vivo assays. Consequently, the GM2 expression in the
MPM cell lines was confirmed using flow cytometry. In addition, eight of 11 cell
lines were GM2-positive (73%), although the GM2 expression was variable. BIW-
8962 showed a significant antibody-dependent cellular cytotoxicity activity
against the GM2-expressing MPM cell line MSTO-211H, the effect of which
depended on the antibody concentration and effector ⁄ target ratio. In an in vivo
orthotropic mouse model using MSTO-211H cells, BIW-8962 significantly
decreased the incidence and size of tumors. Additionally, the GM2 expression
was confirmed in the MPM clinical specimens. Fifty-eight percent of the MPM
tumors were positive for GM2, with individual variation in the intensity and
frequency of staining. These data suggest that anti-GM2 antibodies may become
a therapeutic option for MPM patients.
M alignant pleural mesothelioma (MPM) is a rare andhighly aggressive neoplasm that arises from the pleural,
pericardial, or peritoneal lining. Malignant pleural mesotheli-
oma was previously considered to be very rare; however, the
worldwide incidence is expected to increase substantially in
the next decades, as MPM is usually associated with chronic
asbestos exposure and there is a long latency period between
the time of exposure and tumor development.(1,2) Although
surgery, chemotherapy, radiotherapy, and combinations of
these therapies are used to treat MPM, the median survival of
such patients is dismal, at only 6–18 months.(3–5) Despite the
use of a novel systemic chemotherapy regimen using the com-
bination of pemetrexed and cisplatin, the long-term survival of
patients with MPM remains limited.(6) Therefore, further spe-
cific, effective, and less toxic therapies are needed.(7)
The importance of antibody therapeutics is increasing due to
the high efficacy and low toxicity of these agents. The mode
of action of antibody therapeutics can be divided into two
main types: antigen neutralization, and the killing of antigen-
expressing cells due to antibody effector functions. The major
effector functions of therapeutic antibodies include antibody-
dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC), both of which are mediated by
the recruitment of immune cells, including natural killer (NK)
cells and complement, respectively.(8) The ADCC activity, in
particular, is considered to play an important role in the effi-
cacy of antibody therapeutics for hematological and solid
tumors. For example, trastuzumab has been shown to have
clinical benefits in the setting of breast cancer. The beneficial
effects of this drug depend on the patient’s gene polymorphism
of FccRIIIA, the receptor for IgG expressed in NK cells.(9,10)
These data strongly suggest that ADCC activity is involved in
the therapeutic activity of trastuzumab.
Ganglioside GM2, a glycolipid consisting of ceramide and
oligosaccharide, is a component of the cell membrane. The
activity of GM2 is suggested to be associated with neuronal
cell survival.(11) In addition, GM2 has been reported to be
overexpressed in tissues of lung cancer, neuroblastoma, and
glioma, although it is rarely expressed in normal cells.(12,13)
Therefore, GM2 is considered to be an attractive target for
therapeutic antibodies against cancer. Jones et al.(14) reported
that melanoma patients with an elevated anti-GM2 antibody
titer show prolonged survival. This finding indicates the
potential importance of antibodies that recognize GM2 in the
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immunological response against cancer. Although vaccination
using GM2-conjugated proteins has been attempted clinically,
sufficient efficacy has not yet been achieved.(15) Against this
background, humanized anti-GM2 antibodies with potent
ADCC and CDC activities have been generated.(16) Recently,
the ADCC-enhancing modification of fucose removal from
core Fc-linked oligosaccharides was applied to this antibody,
and a non-fucosylated humanized anti-GM2 antibody, BIW-
8962, was successfully developed. BIW-8962 was subse-
quently shown to have an in vivo therapeutic activity in a
SCID mouse model of multiple organ metastasis induced by
GM2-positive small-cell lung cancer (SCLC) cell lines, and
overexpression of GM2 was detected in SCLC clinical speci-
mens.(17) In order to further investigate the therapeutic poten-
tial of the non-fucosylated, humanized anti-GM2 antibody
BIW-8962 as a novel anti-MPM agent, we evaluated the effi-
cacy of BIW-8962 against MPM cell lines using in vitro
ADCC and in vivo orthotropic mouse models. In addition, we
analyzed GM2 expression levels in clinical samples of MPM.
Materials and Methods
Cell lines. Eleven human MPM cell lines were used in this
study. ACC-MESO-1, Y-MESO-8A, Y-MESO-12, and Y-
MESO-14 were established at the Aichi Cancer Research Center
Institute (Nagoya, Japan).(18) NCI-H290 and NCI-H513 were
provided by Dr. Adi F. Gazdar (University of Texas Southwest-
ern Medical Center, Dallas, TX, USA). MSTO-211H, NCI-H28,
NCI-H226, NCI-H2052, and NCI-H2452 were purchased from
ATCC (Rockville, MD, USA). These cells were cultured in
RPMI-1640 medium supplemented with 10% FBS (Life Tech-
nologies, Grand Island, NY, USA), 100 U ⁄mL penicillin, and
100 mg ⁄mL streptomycin (Meiji Seika Kaisha, Tokyo, Japan).
Animals. Male SCID mice, 5–6 weeks of age, were obtained
from CLEA Japan (Osaka, Japan) and maintained under specific
pathogen-free conditions throughout this study. All animals
were acclimatized for at least 1 week before the experiments.
All animal experiments complied with the Guidelines for the
Institute for Experimental Animals, Kanazawa University
Advanced Science Research Center (Kanazawa, Japan).
Reagents. The anti-GM2 antibody BIW-8962 and isotype
control anti-dinitrophenol (DNP) antibody (fucose-removed
human IgG1) were prepared by Kyowa Hakko Kirin Co.,
Ltd.
Flow cytometry. The GM2 expression in the MPM cells was
examined using flow cytometry.(19) Briefly, cells (5 9 105)
were resuspended in PBS, supplemented with 10% pooled AB
serum to prevent non-specific binding to the Fc receptor,
washed with cold PBS, and incubated on ice for 30 min with
BIW-8962 or the isotype control. The cells were washed with
cold PBS and incubated on ice for an additional 30 min with
FITC-conjugated anti-human IgG antibodies (Beckman Coul-
ter, Fullerton, CA, USA) then washed and resuspended in cold
PBS. The cells were subsequently analyzed on a FACSCalibur
flow cytometer using the CellQuest software program (Becton
Dickinson, San Jose, CA, USA). The relative fluorescence
intensity was calculated as the ratio of the mean fluorescence
intensity of BIW-8962 to that of the isotype control.
Antibody-dependent cellular cytotoxicity activity. The in vitro
ADCC activity was measured using the lactate dehydrogenase
(LDH) release assay method. Human peripheral blood mono-
nuclear cells (MNCs) prepared from healthy donors using
Lymphoprep (Axis Shield, Dundee, UK) were used as effector
cells, and the human MPM cell line MSTO-211H was used for
the target cells. Detached MSTO-211H cells were plated at a
density of 1 9 104 cells ⁄well into round-bottom 96-well mi-
croplates, and freshly isolated MNCs were added to the same
plates in order to achieve an appropriate effector ⁄ target (E ⁄T)
ratio (E ⁄T = 25 ⁄1, 50 ⁄1, and 100 ⁄1). Serial dilutions of BIW-
8962 were then added to the plates to start the reaction. Fol-
lowing incubation at 37°C for 4 h, the supernatants from each
well were recovered by centrifugation at 50 g for 5 min. The
LDH activity in each supernatant was measured using a non-
radioactive cytotoxicity assay kit (Promega, Madison, WI,
USA). The absorbance at 490 nm was determined using an
ELISA reader. The specific cytotoxicity level was calculated
according to the following formula:
%Cytotoxicity ¼ 100ðExp Espo TspoÞ=ðTotal EspoÞ
where Exp is the amount of LDH experimentally released from
the target cells incubated with the effector cells and antibodies,
Espo is the amount of LDH spontaneously released from the
effector cells, Tspo is the amount of LDH spontaneously
Fig. 1. Expression levels of ganglioside GM2 were
evaluated in malignant pleural mesothelioma cell
lines. Cells were detached and incubated with BIW-
8962 or anti-dinitrophenol (DNP) antibodies on ice
for 30 min. Bound Abs were detected with FITC-
conjugated goat anti-human IgG Abs. The
fluorescence intensity of the stained cells was
measured using flow cytometry, and the mean
fluorescence intensity was calculated. The open red
histograms represent BIW-8962-stained samples and
the filled blue histograms represent anti-DNP
antibody-stained samples. The relative fluorescent
intensity (RFI) versus anti-DNP is indicated.
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released from the target cells, and Total is the maximum
amount of LDH released from the target cells incubated with
9% Triton X.
Orthotropic in vivo assay. Cultured MSTO-211H cells were
harvested using trypsin, washed twice, and resuspended in
PBS, and 1 9 106 cells in 100 lL PBS were subsequently
injected into the thoracic cavity of each SCID mouse, which
was pretreated with TM-b1 antibodies (previously established
mouse IL-2Rb antibodies)(20) 2 days before cancer cell inocu-
lation.(21) The mice were then i.v. given BIW-8962 (10 lg
⁄ animal) and ⁄ or 1 9 106 cells ⁄ animal MNC prepared accord-
ing to the above method on days 7 and 14. At 3 weeks after
tumor cell inoculation, the mice were sacrificed, their thoracic
tumors were carefully removed and weighed, and the volume
of pleural effusion was measured.
Immunofluorescent staining. Twenty-six MPM clinical
tumor specimens were purchased from Origene Technologies
(Rockville, MD, USA). Tumor specimens obtained by ortho-
topic inoculation of H290 cells in SCID mice were also
used as a positive control. Frozen sections of these samples
were fixed with acetone, washed with PBS, and incubated
with 1 lg ⁄mL of DAPI (Vector Laboratories, Burlingame,
CA, USA) at room temperature for 20 min. The sections
were then washed with PBS, blocked with 5% FBS in PBS
for 10 min and incubated with 30 lg⁄mL of Alexa Fluor488
(Invitrogen, Carlsbad, CA, USA) conjugated BIW-8962 or
isotype control at 4°C for 6 h. After being washed with
PBS, the sections were analyzed using fluorescence micros-
copy. The percentages of cells with positive cytoplasmic
and ⁄ or membrane GM2 immunoreactivity were evaluated as
0–100% and the modal intensity of the positively staining
cells were determined on a scale from 0 to 3+: 0, complete
absence of staining; 1+, weaker staining than H290 cells;
2+, similar staining to H290 cells; 3+, clearly more intense
staining than H290 cells (Fig. S1).
Statistical analysis. Differences in the results of the in vitro
experiments were evaluated using Student’s two-tailed t-test,
and differences in the results of the in vivo experiments were
analyzed according to Dunnett’s multiple comparison test. In
all analyses, differences were considered to be significant at a
P-value of <0.05.
Results
GM2 expression in MPM cell lines. First, we carried out a flow
cytometric analysis to determine the GM2 expression levels in
the MPM cell lines. In this assay, 11 histologically different
MPM cell lines were used, as follows: ACC-MESO-1, Y-
MESO-12, NCI-H290, NCI-H513, NCI-H226, and NCI-H2452
as epithelioid type cells; NCI-H28 and NCI-H2052 as sarco-
matoid type cells; and Y-meso-8A, Y-meso-14, and MSTO-
211H as biphasic type cells. Membrane-bound GM2 antigens
were detected using the anti-GM2 antibody BIW-8962. The
GM2 expression levels in these cell lines were categorized into
three groups based on the relative fluorescence intensity: high
(>10) in four cell lines (36%); low (2–10) in four cell lines
(36%); and negative (<2) in three cell lines (28%) (Fig. 1).
We found no cell type-dependent high expression of GM2,
and no GM2 expression was detected in the sarcomatoid MPM
cell lines.
Antibody-dependent cellular cytotoxicity activity against MPM
cell line. The in vitro ADCC activity of BIW-8962 against
the MPM cell line was determined using MNCs obtained
from four healthy volunteers as effector cells and MSTO-
211H, as target cells, which highly express GM2. Conse-
quently, BIW-8962 showed significant ADCC activity at
antibody concentrations of 1 and 10 lg ⁄mL (Fig. 2), the
efficacy of which increased in correlation with the E ⁄T ratio
(25, 50, and 100). The potent ADCC activity of BIW-8962
Fig. 2. Anti-GM2 antibody BIW-8962 exerted antibody-dependent cellular cytotoxicity activity against MSTO-211H malignant pleural mesotheli-
oma cells. Human peripheral blood mononuclear cells were purified from healthy donors and used as effector cells. MSTO-211H cells (target
cells) were incubated with effector cells (effector ⁄ target = 25 ⁄ 1, 50 ⁄ 1, and 100 ⁄ 1) and antibodies (BIW-8962 or anti-dinitrophenol antibodies) at
37°C for 4 h. The released lactate dehydrogenase activity was measured and the % cytotoxicity was calculated. The experiments were carried out
in triplicate, and the values are expressed as the mean of the values for four donors  SD. *P < 0.01, **P < 0.001 BIW-8962 treatment versus
anti-dinitrophenol antibody treatment.
Fig. 3. Anti-GM2 antibody BIW-8962 showed therapeutic activity in
an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleu-
ral mesothelioma cells were inoculated into the thoracic cavity in SCID
mice, and the animals were treated with BIW-8962 and ⁄ or human
peripheral blood mononuclear cells (MNC). The mice were then i.v.
administered BIW-8962 and ⁄ or MNC on days 7 and 14. At 3 weeks
after tumor cell inoculation, the mice were sacrificed and their tumor
weights were measured. The bars represent the mean of the group
data. *P < 0.05 and **P < 0.01 between each treatment and the con-
trol groups.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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was consistently observed in MNCs obtained from the four
donors.
In vivo therapeutic activity of BIW-8962 in orthotropic mouse
model. The therapeutic efficacy of BIW-8962 was evaluated
using an in vivo SCID mouse orthotropic model in which the
animals were inoculated in the thoracic cavity with GM2-posi-
tive MSTO-211H cells and treated with BIW-8962 and ⁄or
human MNCs. BIW-8962 significantly decreased both the inci-
dence and size of tumors (Fig. 3, Table 1). Notably, the con-
comitant administration of BIW-8962 and MNC had a greater
effect on tumor incidence and size, whereas MNC injection
alone showed weak antitumor activity. In addition, the inci-
dence and volume of pleural effusion tended to be decreased
by the co-administration of BIW-8962 and MNC.
Expression of GM2 in MPM clinical specimens. In order to
determine GM2 expression in clinical MPM specimens, immu-
nofluorescent staining of frozen MPM tissue samples obtained
from 26 patients was carried out. The GM2 expression was sub-
sequently confirmed in 58% of the donors, although the inten-
sity and frequency of staining varied greatly from donor to
donor (Fig. 4, Table 2). In contrast, we found no correlation
between GM2 expression pattern and MPM tissue type or stage.
GM2 positivity was detected in four of eight biphasic type
samples (50%), three of five desmoplastic type samples (60%),
and one of two epithelial type samples (50%). Similarly, GM2-
positive cells were detected in two of three stage I tumors
(67%), three of four stage II tumors (75%), five of seven stage
III tumors (71%), and two of five stage IV tumors (40%).
Discussion
Ganglioside GM2 is recognized to be a cancer-associated anti-
gen. A previous histological analysis showed that GM2 is
widely expressed in human lung cancer cells, including SCLC
and Non-small-cell Lung cancer (NSCLC).(22) However, GM2
expression in MPM has not yet been characterized. To the best
of our knowledge, this study is the first experimental report to
show GM2 expression in MPM cell lines and clinical MPM
tumors. Furthermore, in this study, the non-fucosylated human-
ized anti-GM2 antibody, BIW-8962, showed an antitumor
effect and a trend toward decreasing pleural effusion in the in
vivo mouse orthotropic model. These results suggest the possi-
bility that the anti-GM2 antibody BIW-8962 may be applied
therapeutically in MPM patients.
Expression of GM2 was confirmed in eight of 11 MPM cell
lines, four of which showed high levels of GM2 expression. A
previous study showed that the main mode of actions of BIW-
8962 are ADCC and CDC.(17) Actually, BIW-8962 was shown
to exert ADCC activity against the highly GM2-positive
MPM cell line MSTO-211H in a dose-dependent and E ⁄T
Table 1. Therapeutic evaluation of anti-GM2 antibody BIW-8962 in an in vivo orthotropic malignant pleural mesothelioma model
Treatment Dose





Median Range Median Range
Control DW 8 ⁄ 8 550 380–650 3 ⁄ 8 0 0–300
MNC 1 9 106 cells 8 ⁄ 8 590 340–640 2 ⁄ 8 0 0–200
BIW-8962 10 lg 7 ⁄ 8 360 0–590 1 ⁄ 8 0 0–250
BIW-8962 + MNC 10 lg, 1 9 106 cells 4 ⁄ 8 <10 0–510 1 ⁄ 8 0 0–150
DW, distilled water; MNC, human peripheral blood mononuclear cells.
(a) (b)
(c) (d)
Fig. 4. Ganglioside GM2 expression in clinical
malignant pleural mesothelioma specimens. Frozen
sections obtained from 26 mesothelioma patients
were incubated in DAPI at room temperature for
20 min. After washing, the sections were incubated
in 5% FBS–PBS for 10 min for blocking and
subsequently incubated in 30 lg ⁄ mL BIW-8962 or
anti-dinitrophenol antibodies conjugated with
Alexa Fluor488 at 4°C for 6 h. Representative
images are shown. Samples of patients #12 (a), 19
(b), 20 (c), and 23 (d) are shown.
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ratio-dependent manner. In contrast, CDC activity against
MPM cell lines was not observed when BIW-8962 was used at
the high concentration of 100 lg ⁄mL (data not shown). In
addition, BIW-8962 treatment resulted in a significant reduc-
tion in the incidence and size of tumors in the in vivo ortho-
tropic mouse model. As the concomitant administration of
human MNC augmented the therapeutic activity of BIW-8962
in this study, the main mechanism of therapeutic action is
thought to involve ADCC. One of the primary subsets of
lymphocytes exerting an ADCC activity is NK cells, which
are believed to be present in the tumors of MPM patients.(23)
These data suggest that the ADCC activity is stimulated in
MPM tumors by treatment with BIW-8962, thus eliciting an
antitumor effect. The therapeutic effect of BIW-8962 was
observed at a dose of 10 lg ⁄ animal (roughly equal to 0.5 mg
⁄kg) given i.v., and the efficacy of the therapy appeared to be
higher than that of other antibody therapeutics reported previ-
ously.(24,25) The antibody distribution in human MPM has not
been defined. In an MPM mouse xenograft model, it was
reported that biodistribution of 86Y labeled cetuximab and
panitumumab in tumor was approximately 30% ID ⁄g.(26)
Extrapolating from this report, antibody concentration in
tumor when 0.5 mg ⁄kg dose of antibody is given i.v. is
calculated to be approximately 3 lg ⁄mL. This is the sufficient
concentration for BIW-8962 to exert ADCC activity, based
on the in vitro experiment result. However, a previous study
reported that antibody distribution in tumor was approxi-
mately 0.001% ID ⁄g in colorectal cancer patients, lower than
the mouse xenograft model.(27) If we extrapolate the biodistri-
bution ratio to MPM, a dose of 10 mg ⁄kg can achieve an
antibody concentration of more than 5 lg ⁄mL in tumor,
which is required for ADCC exertion.
In this study, GM2 expression was also confirmed in the
clinical specimens of MPM patients, with individual differ-
ences in the expression levels and a rate of GM2 positivity of
58%. Although no correlations were observed between the
GM2 expression profile and the histological findings or stage,
all of the tissue types were GM2-positive. In the setting of
MPM, differences in the histological type are known to affect
the patient’s prognosis, with cases of biphasic and sarcoma-
toid MPM having an especially poor prognosis.(28,29) In this
study, the antitumor activities of BIW-8962 were observed in
the in vitro and in vivo models using the biphasic MPM cell
line MSTO-211H. If this antibody possesses therapeutic activ-
ity in biphasic and sarcomatoid MPM tissues in the clinical
setting, it would be a valuable treatment option for MPM
patients.
In the in vivo orthotropic mouse model using the human
MPM cell line, the mice given BIW-8962 had a tendency to
develop a smaller amount of pleural effusion. As NK cells
have been shown to be present in the fluid of pleural effu-
sion,(30) it is possible that ADCC reactions may occur in the
pleural effusion of MPM patients. More than 60% of MPM
patients present with pleural effusion associated with
breathlessness, often accompanied by chest wall pain, which
subsequently compromises their quality of life.(31) BIW-8962
treatment may help to improve the prognosis of these patients
as well as increase their quality of life by inhibiting the accu-
mulation of pleural effusion.
Cytotoxic agents such as pemetrexed and cisplatin are pri-
marily used in MPM therapy. Hence, the development of a
novel therapeutic agent with a different mode of action is
eagerly anticipated. In this study, we showed that GM2 is
overexpressed in MPM clinical specimens and that the non-fu-
cosylated anti-GM2 antibody BIW-8962 has therapeutic
activity in an in vivo orthotropic MPM model. As the ADCC
activity of antibody therapeutics plays an important role in the
efficacy of oncologic treatment, anti-GM2 antibodies may
become an effective therapy for MPM. A clinical study of
BIW-8962 as monotherapy in subjects with NSCLC, SCLC,
and mesothelioma is currently being carried out
(NCT01898156).
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#1 0 0 Biphasic 58 M II
#2 30 2 Biphasic 69 M I
#3 0 0 Meso 53 M IV
#4 0 0 Meso 57 F III
#5 30 3 Meso 73 M NR
#6 0 0 Biphasic 52 M III
#7 0 0 Biphasic 71 M IV
#8 80 2 Biphasic 50 M IV
#9 30 1 Meso 65 M III
#10 0 0 Meso 71 M IIA
#11 0 0 Desmoplastic 81 M NR
#12 50 3 Meso 66 M II
#13 0 0 Meso 86 M NR
#14 100 2 Desmoplastic 55 M I
#15 0 0 Desmoplastic 63 NR I
#16 90 1 Epithelial 61 M IV
#17 10 1 Meso 68 M III
#18 40 3 Biphasic 62 M III
#19 80 3 Desmoplastic 57 M NR
#20 100 3 Meso 69 M II
#21 100 1 Biphasic
+ desmoplastic
68 M III
#22 100 3 NR 65 M NR
#23 50 3 Meso 69 M II
#24 20 2 Meso 57 F III
#25 0 0 Biphasic 50 M IV
#26 0 0 Epithelial 81 M NR
Criteria for staining intensity: 0, negative; 1, faint; 2, moderate; 3,
strong. F, female; M, male; Meso, unclassified mesothelioma; NR, not
reported.
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